Every 8-K that Neurocrine Biosciences Inc (NBIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NBIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NBIX filings page.
Neurocrine Biosciences (NBIX) appointed Eiry W. Roberts, M.D., as chief medical officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026 by mutual agreement. Keswani is entitled to severance benefits under the company’s Executive Severance Plan, subject to its terms.
The company said it will enter into an amended and restated employment agreement with Roberts, effective September 28, 2026. Under its described terms, she would receive an annual base salary of $825,000 and a 2026 annual cash incentive bonus target equal to 60% of base pay earned. Target equity grant values are approximately $625,000 in stock options, $250,000 in restricted stock units and $375,000 in performance-vesting restricted stock units. Options vest in equal monthly installments over four years, and restricted stock units in equal annual installments over four years; performance units follow the terms for executive officers’ February 2026 grants. The equity grants will automatically be made two business days after the company files its first Form 10-Q following the transition, provided Roberts remains employed on that date.
Neurocrine Biosciences, Inc. filed an amendment to a prior current report to add full financial detail for its completed acquisition of Soleno Therapeutics. The update includes Soleno’s audited 2025 results, unaudited first‑quarter 2026 results, and unaudited pro forma condensed combined statements of income prepared under Article 11 of Regulation S‑X.
On a pro forma basis, combined revenues were $1,907.5 million for the six months ended June 30 2026 and $3,050.9 million for 2025, with pro forma net income of $294.0 million and $324.5 million, respectively. The acquisition adds VYKAT XR, valued at an estimated $2,237.8 million as an identifiable intangible asset with a 16‑year life, driving significant new amortization expense. Neurocrine also highlights a five‑year $1.0 billion senior secured revolving credit facility, from which it drew and fully repaid $600.0 million shortly after closing.
Neurocrine Biosciences reported strong second-quarter 2026 results. Total revenues were $959 million, a 39% year-over-year increase, driven by INGREZZA net product sales of $716 million, CRENESSITY sales of $184 million and initial VYKAT XR sales of $54 million following the May 18 closing of the Soleno Therapeutics acquisition. Unaudited pro-forma total revenue, including a full quarter of VYKAT XR, was $998 million.
GAAP net income for the quarter was $144 million, or $1.39 per diluted share, while Non-GAAP net income was $297 million, or $2.85 per diluted share. The company raised 2026 INGREZZA net sales guidance to $2.825–$2.875 billion. Neurocrine completed the $2.9 billion Soleno acquisition, recorded approximately $2.2 billion of VYKAT XR-related intangible assets, and ended June 30, 2026 with about $482 million in cash, cash equivalents and marketable securities plus an undrawn $1.0 billion senior secured revolving credit facility to support ongoing R&D and commercial investments.
Neurocrine Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 27, 2026. Stockholders elected three Class III directors for terms expiring at the 2029 Annual Meeting and confirmed the existing Class I and Class II board structure.
Of 100,581,991 shares entitled to vote as of March 31, 2026, 90,118,625 were represented in person or by proxy. Stockholders approved on an advisory basis the compensation of named executive officers, and they approved the Amended 2025 Equity Incentive Plan as described in the company’s definitive proxy statement.
Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, confirming the company’s current external audit relationship.
Neurocrine Biosciences completed its all-cash acquisition of Soleno Therapeutics for approximately $2.9 billion. The deal was executed via a tender offer at $53.00 per Soleno share, followed by a short-form merger that makes Soleno a wholly owned subsidiary.
As of the offer expiration, 46,356,114 Soleno shares had been validly tendered, representing 88.9% of Soleno’s outstanding stock. The acquisition adds VYKAT XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine’s commercial portfolio alongside INGREZZA and CRENESSITY.
On May 14, 2026, Neurocrine also entered into a five-year senior secured revolving credit facility of $1.0 billion and made an initial borrowing of $600.0 million under this facility, which is secured by substantially all of the company’s and certain subsidiaries’ assets.
Neurocrine Biosciences reported very strong first-quarter 2026 results, with total revenues of $814.5 million, up 42% from the prior year, driven by growth in key neurology and endocrine drugs.
Net product sales reached $811.0 million, a 44% increase year-over-year. INGREZZA delivered $656.9 million in sales, up 20%, while newly launched CRENESSITY generated $153.3 million. GAAP net income jumped to $197.9 million, with diluted EPS of $1.91, and Non-GAAP EPS was $1.94.
The company entered a definitive agreement to acquire Soleno Therapeutics for an equity value of $2.9 billion, adding VYKAT XR for hyperphagia in Prader-Willi syndrome, and reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8 billion. Cash, cash equivalents, and marketable securities totaled about $2.65 billion as of March 31, 2026.
Neurocrine Biosciences agreed to acquire Soleno Therapeutics via a cash tender offer at $53.00 per share, valuing Soleno’s equity at $2.9 billion. The price reflects a 34% premium to Soleno’s April 2, 2026 close and a 51% premium to its 30‑day VWAP. After the tender offer, any remaining Soleno shares will be converted into the same cash amount through a follow‑on merger, making Soleno a wholly owned Neurocrine subsidiary.
The deal is funded with cash on hand plus modest pre‑payable debt and is not subject to a financing condition, but it requires a majority of Soleno shares to be tendered and clearance under the Hart‑Scott‑Rodino Act. Soleno must observe no‑shop restrictions, with a $95.25 million termination fee if it moves to a superior proposal and a $141.5 million reverse termination fee payable by Neurocrine if certain antitrust conditions are not met. Neurocrine highlights Soleno’s VYKAT XR, which generated $190 million of 2025 revenue, as a way to expand its endocrinology and rare‑disease portfolio and add a third first‑in‑class commercial medicine.
Neurocrine Biosciences reported strong growth for the fourth quarter and full year 2025. Total revenues reached $805.5 million in Q4 and $2.86 billion for 2025, up from $2.36 billion in 2024, driven mainly by its neurology portfolio.
INGREZZA generated net product sales of $657.5 million in Q4 and $2.51 billion for 2025, with single‑digit growth as prescription volumes rose but were partially offset by lower net price from new formulary investments. CRENESSITY contributed $135.3 million in Q4 and $301.2 million for 2025 as a new growth driver.
GAAP net income increased to $153.7 million in Q4 and $478.6 million for 2025, while Non‑GAAP net income was $194.6 million in Q4 and $654.5 million for the year. Cash, cash equivalents, and marketable securities totaled $2.54 billion at December 31, 2025, supporting heavy R&D and commercial investment.
For 2026, the company guides INGREZZA net product sales to $2.7–$2.8 billion, and plans GAAP R&D spending of $1.2–$1.25 billion and GAAP SG&A of $1.38–$1.40 billion as it advances Phase 3 programs in depression and schizophrenia and continues the CRENESSITY launch.
Neurocrine Biosciences, Inc. (NBIX) reported an update to its senior leadership arrangements. Former Chief Medical Officer Eiry W. Roberts, M.D., who transitioned to the role of Strategic Advisor effective June 2, 2025, will continue in that advisory role for an additional 12 months. On November 21, 2025, the company and Dr. Roberts entered into an amendment to her amended and restated employment agreement to extend her employment term through December 31, 2026.
The amendment is filed as an exhibit to this report, reflecting the company’s decision to retain Dr. Roberts’ expertise in a strategic advisory capacity following the appointment of Sanjay Keswani, M.D. as Chief Medical Officer.
Neurocrine Biosciences, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025. The company disclosed this by filing a current report and attaching the full earnings press release as Exhibit 99.1. The press release, dated October 28, 2025, contains the detailed figures and discussion of its results of operations and financial condition for the quarter.